logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
after Q4 2021
Cidara Therapeutics, Inc.
Top-line data from phase III study of Rezafungin (ReSTORE)
modified intention-to-treat (mITT) patients with candidemia and/or invasive candidiasis
after Q4 2021
Satsuma Pharmaceuticals
Filing of NDA for STS101
Migraine
after Q4 2021
Momenta Pharmaceuticals Inc
Top-line data from phase II/III study of Nipocalimab (M281)
Warm Autoimmune Hemolytic Anemia (wAIHA)
after Q4 2021
Biohaven Pharmaceutical Holding Co Ltd.
Topline data from phase III trial of Troriluzole
Spinocerebellar Ataxia in adults
after Q4 2021
Biohaven Pharmaceutical Holding Co Ltd.
Topline results from phase III clinical trial of Verdiperstat(M-STAR)
Multiple System Atrophy
after Q4 2021
Arena Pharmaceutical Inc.
Topline data from Phase 3 trial of Etrasimod ELEVATE UC 52
Ulcerative Colitis (UC)
after Q4 2021
Arena Pharmaceutical Inc.
Topline data from Phase 3 trial of Etrasimod ELEVATE UC 12
Ulcerative Colitis (UC)
after Q4 2021
Kezar Life Sciences, Inc.
Interim data from phase 2 trial of KZR-616 (MISSION)
Systemic Lupus Erythematosus With and Without Nephritis
after Q4 2021
Aldeyra Therapeutics, Inc.
Submission of NDA for Reproxalap
Dry Eye Disease
after Q4 2021
BridgeBio Pharma, Inc.
Topline data from phase 3 study of Acoramidis (ATTRibute-CM)
ATTR cardiomyopathy (ATTR-CM)
after Q4 2021
Celldex Therapeutics Inc.
Initial data from Phase 1 study of CDX-527
Solid tumors
after Q4 2021
Eidos Therapeutics, Inc.
Topline results from Part A of phase III trial of AG10 (ATTRibute-CM)
Transthyretin (TTR) amyloid cardiomyopathy
after Q4 2021
IDEAYA Biosciences
Interim data from evaluation of IDE196 / binimetinib combination therapy
Metastatic Uveal Melanoma (MUM)
after Q4 2021
ABEONA THERAPEUTICS INC.
Topline results from Phase 3 trial of EB-101 (VIITAL)
Recessive dystrophic epidermolysis bullosa (RDEB)
after Q4 2021
Alnylam Pharmaceuticals Inc.
18-month topline results from HELIOS-A Phase 3 study of vutrisiran
hATTR amyloidosis patients with polyneuropathy
after Q4 2021
EDITAS MEDICINE, INC.
Initial data from Phase 1/2 clinical trial of EDIT-101 (BRILLIANCE)
Leber congenital amaurosis 10 (LCA10)
after Q4 2021
NexImmune, Inc.
Initial data from phase I/II study of NEXI-001
Acute myeloid leukemia
after Q4 2021
Angion Biomedica Corp.
Topline data from phase III study of ANG-3777
Acute kidney injury associated with delayed graft function
after Q4 2021
Sensei Biotherapeutics, Inc.
Data from phase 1/2 clinical trial of SNS-301 in combination with Keytruda
Squamous cell carcinoma of the head and neck, or SCCHN
Sep 2021
Adaptimmune Therapeutics plc
Update from phase I trial of ADP-A2AFP
Liver cancer
after Q4 2021
Catalyst Biosciences Inc.
Interim data from phase I/II study of MarzAA (MAA-202)
Bleeding in FVII deficiency, Glanzmann Thrombasthenia, and Hemophilia A with inhibitor patients receiving Hemlibra prophylaxis
2H 2021
4D pharma plc
Topline data from phase I part of MRx-4DP0004 trial
Asthma
2H 2021
Entasis Therapeutics Holdings Inc
Topline data from phase III registration trial of SUL-DUR ( ATTACK)
Patients with pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii
2H 2021
Galmed Pharmaceuticals Ltd.
Topline data from phase I trial of Amilo-5MER
Acute and chronic inflammatory conditions including inflammatory bowel disease
2H 2021
Sio Gene Therapies Inc.
12-month clinical safety and efficacy from the low-dose cohort of AXO-AAV-GM1
GM1 gangliosidosis